Shots:
- The P-III (HERIZON-GEA-01) trial assessed Ziihera + CT ± Tevimbra vs Herceptin + CT as the 1L treatment in 914 adults with HER2+ locally advanced or metastatic GEA
- Ziihera + CT & Ziihera + Tevimbra + CT showed prolonged PFS with 35% risk reduction delivering mPFS of 12.4mos., with mOS of 24.4 & 26.4mos., respectively, incl. a 28% reduction in death risk, vs mPFS of 8.1mos. & mOS of 19.2mos. with Herceptin + CT; additional OS interim analysis for Ziihera + CT is planned for mid-2026
- Key 2EPs showed higher ORR (70.7% & 69.6% vs 65.7%), longer mDoR (20.7 & 14.3 vs 8.3mos.), higher 18mos. PFS (43.9% & 38% vs 20.9%) & 30mos. OS (43.8% & 42.2% vs 30%) for Ziihera + Tevimbra + CT, Ziihera + CT & control arm, respectively, with consistent benefit across subgroups
Ref: Jazz Pharmaceuticals | Image: Jazz Pharmaceuticals | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
